NOD2 and hepatocellular carcinoma: We demonstrate that Nod2−/− mice treated with DMBA and maintained on HFD for 31 weeks had altered expression of genes in pathways associated with the development of cancer, liver hyperplasia, liver carcinoma, liver steatosis, hepatocellular carcinoma, inflammation, and cholesterol biosynthesis.